Cannvas MedTech (CSE:MTEC), a leading digital cannabis educator and business technology company, is pleased to report it continues toward its goal of becoming the leading social and census data collection agency of the cannabis industry. With over one million cannabis consumer data points collected since the launch of its digital cannabis education platform Cannvas.Me, Cannvas is well-positioned to accelerate its data collection and analysis within the industry.

“With the breadth of data we collect from the cannabis industry, from Canada to Germany and other countries across the world where we have a growing user base, Cannvas Data is positioning itself to deliver timely, accurate and relevant information to organizations looking to tailor their production and marketing efforts to an ever-evolving audience of consumers, health advocates, physicians, lawmakers, investors and producers,” said Shawn Moniz, Chief Executive Officer, Cannvas MedTech Inc. “The idea is that companies can drill down to determine the needs of a retired 65-year-old man in Montreal with sleep issues, compared to those of a working 65-year-old man in rural Alberta with chronic pain, and deliver information and products pertinent to those conditions. We as an industry must deliver a personalized experience to our consumer base if we are to continue increasing our credibility.”

With thousands of users signed up and active on the Cannvas.Me platform since its October 2018 launch, the site continues to experience sustained growth as it delivers free and physician-backed cannabis education using artificial intelligence to contextualize and adapt to its users while collecting valuable industry and customer data points. The Company’s Cannvas Data branch uses the same advanced technology to closely analyze and process data points to reveal highly-focused and relevant cannabis industry insights.

“Our data sets us apart within the industry, as our Cannvas.Me platform continually collects global data relevant to cannabis sectors that we can then feed back into the industry,” said Steve Loutskou, Chief Operating Officer, Global Markets, Cannvas MedTech Inc. “Expansion of our user base through key partnerships within and outside the cannabis industry translates into a richer set of data and insights into cannabis consumption, a key revenue-generating driver of our business.”

Cannvas Data uses machine-learning algorithms and artificial intelligence (AI) to analyze cannabis industry trends, opportunities and challenges and create detailed reports for a range of sectors including education, medical and health sciences, government and the cannabis sector itself. Through the partnership network established by Cannvas.Me with recognized healthcare and education providers, such as Namaste, Hi-Jane and Advica Health, Cannvas Data is increasing the amount of data it processes nearly every day. NamasteMD alone brings a reach extending across 20 countries with a database of nearly two million users. The result is an ongoing anonymized analysis of what cannabis consumers across Canada are seeking out, from education and methods of ingestion to products, producers and prescriptions.

Through Cannvas Health, the Company has entered into agreements with leading health care and education organizations, as well as dispensaries and cannabis brands, to provide white label solutions for digital cannabis education opportunities powered by the Cannvas.Me platform. This exposure expands the ability of Cannvas Data to comb through vast networks with millions of users volunteering their cannabis inquiries and habits as they navigate learning modules and informational articles on the potential health benefits of cannabis as an alternative treatment. Aiming to be among the international authorities of unbiased and arm’s-length information on the cannabis sector, Cannvas Data continues to work with those in the industry to paint a clearer picture of the marketplace and its needs at present and in the future.

Cannvas MedTech also recently joined the Global Cannabis Partnership (GCP), a collective of leaders in the government-sanctioned, adult-use recreational cannabis industry, as a Member organization. The goal of the GCP is to develop an international standard for the safe and responsible production, distribution and consumption of legal recreational cannabis and help shape the face of social responsibility in the cannabis industry. Its main objectives are to build credibility for government agencies, industry and partners through responsible practices, align and leverage common principles and practices across diverse jurisdictions, and help partners mitigate negative impacts and leverage best practices from within and outside the industry to protect and enhance social licence to operate, with a view to minimizing harm.

Additionally, the Company issued a total of 58,703 common shares (the “Shares”) at a deemed value of $0.30 per Share to certain persons for certain consulting fees owed totaling approximately $17,610.90. Cannvas also issued an aggregate of 1,000,000 Shares of the Company at a deemed value of $0.30 per Share to certain related parties of the Company, pursuant to the achievement of certain milestones and in accordance with their respective consulting agreements.

About Cannvas MedTech Inc.

Cannvas MedTech is a leading digital cannabis education and business technology company within the health sciences space. We design and build patient-centric platforms that enable our partners to harness the power of data to truly understand their customers.

For additional information:

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on

For further information: Investor Relations: Renmark Financial Communications Inc., Shushu Feng:, Tel: (416) 644-2020 or (212) 812-7680

Related Links

Click here to connect with Cannvas MedTech (CSE:MTEC) for an Investor Presentation. 


Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development

Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.

Keep reading... Show less

The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.

With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.

Keep reading... Show less

HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.

DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.

Keep reading... Show less

CFN Enterprises Inc. (OTCQB: CNFN) (CFN Media) partners with FMW Media Works LLC to produce a regular series on the global cannabis markets to air on major financial news networks across the US. Initial segment features leading cannabis analyst and US Multi-State Operator (MSO)

CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced that its inaugural news segment on the cannabis markets, “Cannabis Market Outlook for 2021,” will air on Bloomberg, Newsmax and Fox Business.

Keep reading... Show less